[1]Fairlamb DJ.Spontaneous regression of metastases of renal cancer: A report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature[J]. Cancer, 2015, 47(8):2102-2106.
[2]Greef B, Eisen T. Medical treatment of renal cancer: new horizons[J]. Brit J Cancer, 2016, 115(5):505-516.
[3]杨康, 李魏芳, 喻俊峰. 靶向免疫检查点治疗肾细胞癌的进展[J].实用医学杂志, 2016, 32(7):1068-1069.
[4]Asadi E, Abdouss M, Leblanc RM, et al. In vitro/in vivo study of novel anti-cancer, biodegradable cross-linked tannic acid for fabrication of 5-fluorouracil-targeting drug delivery nano-device based on a molecular imprinted polymer[J]. Rsc Advances, 2016, 6(43):37308-37318.
[5]Xie C, Fu L, Han Y, et al.Decreased ARID1A expression facilitates cell proliferation and inhibits 5-fluorouracil-induced apoptosis in colorectal carcinoma[J].Tumor Biol, 2014, 35(8):7921-7927.
[6]Lou S, Ren L, Xiao J, et al. Expression profiling based graph-clustering approach to determine renal carcinoma related pathway in response to kidney cancer[J]. Eur Rev Med Pharmacol Sci, 2012, 16(6):775-780.
[7]Boguslawska J, Kedzierska H, Poplawski P, et al. Expression of genes involved in cellular adhesion and extracellular matrix remodeling correlates with poor survival of patients with renal cancer[J]. J Urology, 2016, 195(6):1892-1902.
[8]Schdel J, Grampp S, Maher ER, et al. Hypoxia, Hypoxia-inducible transcription factors, and renal cancer[J]. Eur Urol, 2016, 69(4):646-657.
[9]聂明秀, 张洪秀, 李伟. VHL基因和HIF缺氧反应对肾癌的研究进展[J]. 昆明理工大学学报(自然科学版), 2015, 6(3):101-105.
[10]郭放, 郑振东, 谢晓冬. 晚期肾癌分子靶向治疗新进展[J]. 中国肿瘤临床, 2016, 43(22):977-980.
[11]聂磊, 柏帅, 刘卫,等. 氟尿嘧啶和奥沙利铂对消化道肿瘤的协同抑制作用[J]. 实用医药杂志, 2014, 31(1):40-41.
[12]Dobritzsch D, Schneider G, Schnackerz KD, et al. Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil[J]. Embo J, 2014, 20(4):650-660.
[13]Peter B, Lili D, Szilvia J, et al. The PCNA-associated protein PARI negatively regulates homologous recombination via the inhibition of DNA repair synthesis[J]. Nucleic Acids Res, 2016, 44(7):3176-3189.
[14]Watanabe M, Nagai Y, Kinoshita K, et al. Induction Chemotherapy with Docetaxel/Cisplatin/5-Fluorouracil for Patients with Node-Positive Esophageal Cancer[J]. Digestion, 2011, 83(3):146-152.
[15]Samatiwat P, Prawan A, Senggunprai L, et al. Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells[J]. N-S Arch Pharmacol, 2015, 388(6):601-612.
[16]Ardalan B, Glazer RI, Kensler TW, et al. Synergistic effect of 5-fluorouracil and, ja:math, on cell growth and ribonucleic acid synthesis in a human mammary carcinoma[J]. Biochem Pharmacol, 2015, 30(15):2045-2049.
[17]Damjanovic SS, Ilic BB, Cokic BB, et al. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma[J]. Exp Mol Pathol, 2016, 101(3):323-331.
[18]Shen C, Kaelin WG Jr. The VHL/HIF axis in clear cell renal carcinoma[J]. Semin Cancer Biol, 2013, 23(1):18-25.
[19]Shareef MM, Udayakumar TS, Sinha VK, et al. Interaction of HIF-1α and Notch3 Is required for the expression of carbonic anhydrase 9 in breast carcinoma cells[J]. Genes & Cancer, 2013, 4(11/12):513-523.
[20]Schnenberger D, Harlander S, Rajski M, et al. Formation of renal cysts and tumors in Vhl/Trp53-deficient mice requires HIF-1α and HIF-2α[J]. Cancer Res, 2016, 76(7):2025-2036.
[21]贾云波, 杜惠兰, 高星,等.补肾温阳化瘀方对子宫内膜异位症肾阳虚血瘀证模型大鼠HIF-1α、PHD2、VHL表达的影响[J]. 中国中西医结合杂志, 2015, 35(10):1210-1217.
[22]邵进, 张岩, 王治,等.低氧诱导因子-1α参与骨发育及骨代谢调控的研究进展[J].中国骨质疏松杂志, 2015, 6(3):349-355.
[23]涂福平, 黄莉, 王祥财. 缺氧环境下VHL和HIF-1α的变化[J].医疗装备, 2017, 30(5):93-94.
[24]Liu Q, Tong D, Liu G, et al. HIF2Agermline-mutation-induced polycythemia in a patient with VHL-associated renal-cell carcinoma[J]. Cancer Biol Ther, 2017, 18(12):944-947.
[25]Liontos M, Trigka EA, Korkolopoulou P, et al. Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients[J]. World J Urol, 2017, 35(3):1-9.
[26]Cho H, Du X, Rizzi J P, et al. On-Target efficacy of a HIF2α antagonist in preclinical kidney cancer models[J]. Nature, 2016, 539(7627):107-142. |